Suppr超能文献

疑似系统性肥大细胞增多症患者的指南和诊断算法:奥地利专业网络(AUCNM)的提议

Guidelines and diagnostic algorithm for patients with suspected systemic mastocytosis: a proposal of the Austrian competence network (AUCNM).

作者信息

Valent Peter, Aberer Elisabeth, Beham-Schmid Christine, Fellinger Christina, Fuchs Wolfgang, Gleixner Karoline V, Greul Rosemarie, Hadzijusufovic Emir, Hoermann Gregor, Sperr Wolfgang R, Wimazal Friedrich, Wöhrl Stefan, Zahel Brigitte, Pehamberger Hubert

机构信息

Department of Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna Austria ; Ludwig Boltzmann Cluster Oncology, Medical University of Vienna Austria.

出版信息

Am J Blood Res. 2013 May 5;3(2):174-80. Print 2013.

Abstract

Systemic mastocytosis (SM) is a hematopoietic neoplasm characterized by pathologic expansion of tissue mast cells in one or more extracutaneous organs. In most children and most adult patients, skin involvement is found. Childhood patients frequently suffer from cutaneous mastocytosis without systemic involvement, whereas most adult patients are diagnosed as suffering from SM. In a smaller subset of patients, SM without skin lesions develops which is a diagnostic challenge. In the current article, a diagnostic algorithm for patients with suspected SM is proposed. In adult patients with skin lesions and histologically confirmed mastocytosis in the skin (MIS), a bone marrow biopsy is recommended regardless of the serum tryptase level. In adult patients without skin lesions who are suffering from typical mediator-related symptoms, the basal serum tryptase level is an important diagnostic parameter. In those with slightly elevated tryptase (15-30 ng/ml), additional non-invasive investigations, including a KIT mutation analysis of peripheral blood cells and sonographic analysis, is performed. In adult patients in whom i) KIT D816V is detected or/and ii) the basal serum tryptase level is clearly elevated (> 30 ng/ml) or/and iii) other clinical or laboratory features are suggesting the presence of occult mastocytosis, a bone marrow biopsy should be performed. In the absence of KIT D816V and other indications of mastocytosis, no bone marrow investigation is required, but the patient's course and the serum tryptase levels are examined in the follow-up.

摘要

系统性肥大细胞增多症(SM)是一种造血系统肿瘤,其特征是一个或多个皮肤外器官中的组织肥大细胞发生病理性增生。在大多数儿童和大多数成年患者中,可发现有皮肤受累情况。儿童患者常患皮肤肥大细胞增多症而无全身受累,而大多数成年患者被诊断为患有SM。在一小部分患者中,会出现无皮肤病变的SM,这是一个诊断难题。在本文中,提出了一种针对疑似SM患者的诊断算法。对于有皮肤病变且经组织学证实皮肤存在肥大细胞增多症(MIS)的成年患者,无论血清类胰蛋白酶水平如何,均建议进行骨髓活检。对于无皮肤病变但出现典型介质相关症状的成年患者,基础血清类胰蛋白酶水平是一个重要的诊断参数。对于类胰蛋白酶轻度升高(15 - 30 ng/ml)的患者,需进行额外的非侵入性检查,包括外周血细胞的KIT突变分析和超声检查。对于成年患者,若i)检测到KIT D816V或/和ii)基础血清类胰蛋白酶水平明显升高(> 30 ng/ml)或/和iii)其他临床或实验室特征提示存在隐匿性肥大细胞增多症,则应进行骨髓活检。若未检测到KIT D816V且无其他肥大细胞增多症的迹象,则无需进行骨髓检查,但在随访中需检查患者的病程及血清类胰蛋白酶水平。

相似文献

4
Mastocytosis: state of the art.
Pathobiology. 2007;74(2):121-32. doi: 10.1159/000101711.
5
Serum tryptase correlates with the KIT D816V mutation burden in adults with indolent systemic mastocytosis.
Eur J Haematol. 2013 Aug;91(2):106-11. doi: 10.1111/ejh.12128. Epub 2013 Jun 28.
6
Diagnosis of Primary Mast Cell Disorders in Anaphylaxis: Value of KIT D816V in Peripheral Blood.
J Allergy Clin Immunol Pract. 2021 Aug;9(8):3176-3187.e3. doi: 10.1016/j.jaip.2021.04.062. Epub 2021 May 8.
7
Diagnostic criteria and classification of mastocytosis: a consensus proposal.
Leuk Res. 2001 Jul;25(7):603-25. doi: 10.1016/s0145-2126(01)00038-8.
9
Tryptase detection in bone-marrow blood: a new diagnostic tool in systemic mastocytosis.
J Am Acad Dermatol. 2007 Mar;56(3):453-7. doi: 10.1016/j.jaad.2006.09.020. Epub 2006 Oct 30.

引用本文的文献

1
Mastocytosis: One Word for Different Diseases.
Oncol Ther. 2018 Dec;6(2):129-140. doi: 10.1007/s40487-018-0086-2. Epub 2018 Oct 29.
2
[Severe therapy refractive osteoporosis : A rare differential diagnosis].
Z Rheumatol. 2016 Sep;75(7):729-35. doi: 10.1007/s00393-016-0096-0.
3
Bullous mastocytosis in a 3-month-old infant.
Indian Dermatol Online J. 2014 Oct;5(4):497-500. doi: 10.4103/2229-5178.142520.

本文引用的文献

1
European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives.
Wien Klin Wochenschr. 2012 Dec;124(23-24):807-14. doi: 10.1007/s00508-012-0293-z. Epub 2012 Nov 20.
2
Diagnosis, progression patterns and prognostication in mastocytosis.
Expert Rev Hematol. 2012 Jun;5(3):261-74. doi: 10.1586/ehm.12.12.
3
Severe life-threatening or disabling anaphylaxis in patients with systemic mastocytosis: a single-center experience.
Int Arch Allergy Immunol. 2012;157(4):399-405. doi: 10.1159/000329218. Epub 2011 Nov 25.
6
Mast cell activation syndrome: Proposed diagnostic criteria.
J Allergy Clin Immunol. 2010 Dec;126(6):1099-104.e4. doi: 10.1016/j.jaci.2010.08.035. Epub 2010 Oct 28.
7
Mastocytosis.
Chem Immunol Allergy. 2010;95:110-124. doi: 10.1159/000315946. Epub 2010 Jun 1.
10
Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors.
Blood. 2009 Jun 4;113(23):5727-36. doi: 10.1182/blood-2009-02-205237. Epub 2009 Apr 10.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验